Novel Gel Drug Delivery Developed for Rheumatoid Arthritis

Save

Scientists at the Institute for Basic Science have invented a hydrogel capable of delivering drug at sites of inflammation in disorders such as rheumatoid arthritis.

BSR Guidelines on Lupus Management

Save

In the UK, NICE has accredited the British Society of Rheumatology (BSR) to develop a guidance document on the management of systemic lupus erythematosus in adults.  The last published guidelines for lupus were published in 2008 by EULAR and in 2012 by the ACR.

Zilretta - a New Drug FDA Approved for Osteoarthritis of the Knee

Save

Flexion Therapeutics announced friday that the U.S. Food and Drug Administration (FDA) has approved its osteoarthritis (OA) of the knee injectable steroid drug Zilretta with the indication of moderate-to-severe knee pain.

2016 EULAR Guidelines on RA Management

Save

The management of rheumatoid arthritis (RA) has evolved significantly with time.  Nevertheless, there are still some uncertainties - such as when, what and which biologic or novel therapy should be used.

The RheumNow Week in Review - 6 October 2017

Save

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses when to hold the biologic, lymphoma risk with tofacitinib, early clues to the diagnosis of RA, biologic use in pregnancy, what's killing psoriasis patients and the 2016 top 5, best selling drugs in rheumatology.

Patterns of Biologic Use During Autoimmune Pregnancy

Save

While it is highly desirable to avoid medications during conception and pregnancy, statistics show that >90% of women take at least one drug during pregnancy and nearly half will take 3 or more medications during pregnancy.

Alcohol Related Deaths Increased in Psoriasis

Save

JAMA Dermatology has published a report showing psoriasis carries a 60% greater risk alcohol-related death compared with those without psoriasis. (Citation source: https://buff.ly/2galDwr)

Amgen-Abbvie Settle Humira Biosimilar Patent Dispute

Save

Amgen's biosimilar version of adalimumab (Humira) was FDA-approved in September 2016 and given the trade name Amjevita (generic: adalimumab-atto). This new TNF inhibitor biosimilar has not yet been to market because of legal wranglings over patent issues by Abbvie's Humira.

29 September 2017 The RheumNow Week in Review

Save

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses regulatory actions by NICE and FDA, higher death rates in RA and psoriasis, increased risk of RA with Asthma, rising numbers for OA, RA, and STDs.

Psoriasis Increases Risk of Major Adverse Cardiovascular Events

Save

A report in the Journal of the American Academy of Dermatology shows that psoriasis duration and inflammation may result in cardiovascular inflammation and an increased risk of major adverse CV events.

Safety of Long-Term PPI Use

Save

The current issue of JAMA reviews the safety of long-term use of proton pump inhibitors (PPI). The following is a collection of the evidence about these purported risks.

Fractures

UAB Researchers Shed Light on Age-Related Osteoporosis

Save

Researchers from the University of Alabama at Birmingham (UAB) have detailed mechanisms leading to age-related bone loss and osteoporosis.

No Cancer Risk With Biologic Use

Save

A polulation-based study from Sweden has shown that treatment with tocilizumab, abatacept, rituximab, or tumor necrosis factor (TNFi) inhibitors does not affect the risk of malignant neoplasms among patients with rheumatoid arthritis. Specifically, use of a first or second TNFi or biologic DMARDs (bDMARD) does confer a different cancer risk when compared to conventional DMARDS in biologic–naive RA patients.

Sirukumab Turned Down by FDA

Save

On Friday the U.S. Food and Drug Administration announced that will not approve Johnson & Johnson’s rheumatoid arthritis drug sirukumab, stating further data and study would be needed to establish its safety. 

22 September 2017 The RheumNow Week in Review

Save

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses survey results on membranous nephritis and patient perceptions of steroids, nonadherence, celebrity arthritis and IgG4 treatment.

Rituximab Efficacy in IgG4 Related Disease

Save

PLOS reports  greater than 90% efficacy when rituximab (RTX) is used to treat patients with IgG4-related disease (IgG4-RD). 

Romosuzumab Followed by Alendronate is Best in Fracture Prevention

Save

The NEJM reports that in high risk post-menopausal women, romosozumab for 12 months followed by alendronate resulted in a significantly lower fracture than alendronate alone. 

Half of Takayasu's Arteritis Relapse

Save

A French retrospective study of 318 Takayasu's arteritis (TA) patients shows that 50% of patients will relapse and experience a vascular complication ≤10 years from diagnosis. 

15 September 2017 The RheumNow Week in Review

Save

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses metabolic syndrome in lupus, bisphosphonate holidays, vasculitis and vascular inflammation, vaccination, and the repeated wonders of Vitamin D.

Biologic Use in Adult-Onset Still's Disease

Save

 Adult-onset Still's disease (AOSD) is the adult continum of systemic-onset juvenile idiopathic arthritis (SoJIA). Treatment of this febrile polyarticular systemic disorder can be complex, but has been relieved by several specific biologic therapies.